CTKBCytek Biosciences, Inc.
Is it safe?
Caution warranted: heavy debt (BB) and big price swings.
Net cash, but unprofitable, speculative. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -91% · now 12% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can CTKB take a bad year?
Cytek Biosciences, Inc. holds $262M more cash than debt, and is burning $3.0M a quarter, about 21.7 years of cover.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Cash runway
- 5+ years
Cash runway · burning $3.0M a quarter at the current rate
- Annualised volatility
- 66%
Annualised volatility · three times the market's own swing
Details›
- Total debtQ2 2026
- $246K
- Cash and short-term investments
- $262M
- Net cash
- $262M
- EBITDA, trailing twelve months
- −$39M
- Operating profit, trailing twelve months
- −$45M
- Debt / equity
- 0.00×
- Annualised volatilitytwo years of daily moves
- 66%
- Worst drawdown on file
- −91%
- Below its 52-week high
- 12%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.